Alterity Therapeutics announced a US patent grant and license agreement

Alterity Therapeutics Limited (ASX: ATH) announced that the composition of matter patent previously granted by the US Patent and Trademark Office (USPTO) had been granted. The patent, titled "Compounds for and Methods of Treating Diseases" (No. 11,603,364), covers more than 100 novel compounds with an acyl hydrazone (AH) structure and grants exclusivity for 20 years.

To progress these substances for treating Alzheimer's and related disorders, the company also disclosed a licencing arrangement for the new patent and a sub-licensing agreement for PBT2. According to the license agreement terms, the company grants the entire rights to all AH patent and an exclusive worldwide licence to create and market AH and PBT2 as treatments for Alzheimer's disease (AD).

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com